SCHEMBL582597

SCHEMBL582597

CON(C)C(=O)c1cnc2[nH]ncc2c1NCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 4/20 0.47
CCNE1 P24864 4/20 0.47
CDK2 P24941 4/20 0.47
CCNB2 O95067 2/20 0.47
CDK1 P06493 2/20 0.47
CCNB1 P14635 2/20 0.47
CCNB3 Q8WWL7 2/20 0.47
LMNA P02545 3/20 0.46
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
ADORA1 P30542 3/20 0.41
ADORA2A P29274 1/20 0.41
SRC P12931 1/20 0.40
PDE4B Q07343 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7597515 0.81 MAPT (0.63) CCNE2CCNE1CDK2CCNB2CDK1
SCHEMBL582621 0.78 PDE4B (0.58) ADORA1ADORA2ASRCPDE4B
SCHEMBL583310 0.75 ADORA1 (0.55) LMNAMAPTALDH1A1HPGDKDM4E
SCHEMBL583311 0.75 PDE4B (0.53) CCNE2CCNE1CDK2CCNB2CDK1
SCHEMBL31178646 0.73 BRD4 (0.44) CCNE2CCNE1CDK2CCNB2CDK1
SCHEMBL11816907 0.72 SLC29A1 (0.54) CCNE2CCNE1CDK2CCNB2CDK1
SCHEMBL5259711 0.71 CCNE2 (0.51) CCNE2CCNE1CDK2CCNB2CDK1
SCHEMBL4791270 0.68 PDE4B (0.45) CCNE2CCNE1CDK2CCNB2CDK1
SCHEMBL4339577 0.67 PDE4B (0.53) CCNE2CCNE1CDK2CCNB2CDK1
SCHEMBL305701 0.67 BRD4 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US disclosed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP disclosed
US-20110130403-A1 PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2011-06-02 US disclosed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4A, PDE3A CCNE2 4118/4885CCNE1 3817/4885CDK2 871/4885
US-20110130403-A1 PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3B, PDE4B CCNE2 3564/4885CCNE1 3081/4885CDK2 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.